Kalvista Stock Based Compensation from 2010 to 2025

KALV Stock

USD 11.93 0.41 3.32%

Kalvista Pharmaceuticals Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2013-10-31

Previous Quarter

3 M

Current Value

2.6 M

Quarterly Volatility

2.1 M

Yuan Drop

Covid

Check Kalvista Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalvista Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 985.3 K, Interest Expense of 0.0 or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 46.33, Dividend Yield of 0.0 or Days Sales Outstanding of 268. Kalvista financial statements analysis is a perfect complement when working with Kalvista Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Kalvista Pharmaceuticals Correlation against competitors.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Latest Kalvista Pharmaceuticals' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Kalvista Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Kalvista Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kalvista Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Kalvista Stock Based Compensation Regression Statistics

	Arithmetic Mean	6,944,163
	Geometric Mean	1,125,371
	Coefficient Of Variation	136.42
	Mean Deviation	7,505,079
	Median	2,966,000
	Standard Deviation	9,473,068
	Sample Variance	89.7T
	Range	26.4M
	R-Value	0.87
	Mean Square Error	23.3T
	R-Squared	0.76
	Significance	0.000012
	Slope	1,731,427
	Total Sum of Squares	1346.1T

Kalvista Stock Based Compensation History

	2025	26.5 M
	2024	25.2 M
	2023	21.9 M
	2022	9.9 M
	2021	11.1 M
	2020	7.1 M
	2019	4.4 M

Other Fundumenentals of Kalvista Pharmaceuticals

Stock Based Compensation To Revenue

Kalvista Pharmaceuticals Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.4	-0.63	-0.82	0.76	-0.21	1.0	-0.52	0.8	0.36	0.7	0.78	0.68	0.86	0.77	-0.09	0.19	0.82	0.82	0.48
Total Stockholder Equity	0.99		0.44	-0.63	-0.79	0.74	-0.33	0.99	-0.55	0.82	0.34	0.76	0.77	0.68	0.87	0.78	-0.12	0.16	0.83	0.83	0.49
Current Deferred Revenue	0.4	0.44		-0.78	-0.28	0.34	-0.41	0.41	-0.82	0.41	-0.56	0.14	0.31	0.5	0.5	0.46	0.46	-0.73	0.36	0.38	0.3
Net Debt	-0.63	-0.63	-0.78		0.43	-0.4	0.19	-0.63	0.79	-0.56	0.26	-0.29	-0.6	-0.72	-0.66	-0.59	-0.47	0.45	-0.46	-0.47	-0.28
Retained Earnings	-0.82	-0.79	-0.28	0.43		-0.95	0.03	-0.81	0.31	-0.83	-0.35	-0.6	-0.55	-0.49	-0.51	-0.71	0.11	-0.22	-0.63	-0.63	-0.61
Accounts Payable	0.76	0.74	0.34	-0.4	-0.95		-0.09	0.75	-0.35	0.83	0.26	0.59	0.39	0.44	0.4	0.61	-0.08	0.13	0.6	0.59	0.63
Total Liab	-0.21	-0.33	-0.41	0.19	0.03	-0.09		-0.21	0.36	-0.39	0.12	-0.54	-0.21	-0.25	-0.33	-0.2	0.26	0.2	-0.32	-0.32	-0.24
Total Current Assets	1.0	0.99	0.41	-0.63	-0.81	0.75	-0.21		-0.53	0.8	0.36	0.7	0.77	0.67	0.86	0.77	-0.09	0.18	0.82	0.83	0.48
Short Term Debt	-0.52	-0.55	-0.82	0.79	0.31	-0.35	0.36	-0.53		-0.55	0.2	-0.34	-0.46	-0.67	-0.56	-0.63	-0.29	0.45	-0.36	-0.38	-0.18
Common Stock	0.8	0.82	0.41	-0.56	-0.83	0.83	-0.39	0.8	-0.55		0.36	0.79	0.58	0.59	0.56	0.66	-0.11	0.14	0.76	0.76	0.73
Long Term Debt	0.36	0.34	-0.56	0.26	-0.35	0.26	0.12	0.36	0.2	0.36		0.6	0.35	0.22	0.23	0.33	-0.6	0.96	0.4	0.38	0.25
Long Term Debt Total	0.7	0.76	0.14	-0.29	-0.6	0.59	-0.54	0.7	-0.34	0.79	0.6		0.56	0.65	0.59	0.69	-0.31	0.46	0.68	0.68	0.48
Capital Surpluse	0.78	0.77	0.31	-0.6	-0.55	0.39	-0.21	0.77	-0.46	0.58	0.35	0.56		0.79	0.91	0.73	-0.15	0.19	0.67	0.67	0.32
Property Plant Equipment	0.68	0.68	0.5	-0.72	-0.49	0.44	-0.25	0.67	-0.67	0.59	0.22	0.65	0.79		0.77	0.88	0.2	0.04	0.5	0.51	0.24
Net Tangible Assets	0.86	0.87	0.5	-0.66	-0.51	0.4	-0.33	0.86	-0.56	0.56	0.23	0.59	0.91	0.77		0.75	-0.08	0.07	0.77	0.78	0.33
Net Receivables	0.77	0.78	0.46	-0.59	-0.71	0.61	-0.2	0.77	-0.63	0.66	0.33	0.69	0.73	0.88	0.75		0.04	0.15	0.52	0.52	0.26
Deferred Long Term Liab	-0.09	-0.12	0.46	-0.47	0.11	-0.08	0.26	-0.09	-0.29	-0.11	-0.6	-0.31	-0.15	0.2	-0.08	0.04		-0.63	-0.23	-0.21	-0.17
Short Long Term Debt	0.19	0.16	-0.73	0.45	-0.22	0.13	0.2	0.18	0.45	0.14	0.96	0.46	0.19	0.04	0.07	0.15	-0.63		0.24	0.22	0.13
Net Invested Capital	0.82	0.83	0.36	-0.46	-0.63	0.6	-0.32	0.82	-0.36	0.76	0.4	0.68	0.67	0.5	0.77	0.52	-0.23	0.24		1.0	0.8
Net Working Capital	0.82	0.83	0.38	-0.47	-0.63	0.59	-0.32	0.83	-0.38	0.76	0.38	0.68	0.67	0.51	0.78	0.52	-0.21	0.22	1.0		0.8
Capital Stock	0.48	0.49	0.3	-0.28	-0.61	0.63	-0.24	0.48	-0.18	0.73	0.25	0.48	0.32	0.24	0.33	0.26	-0.17	0.13	0.8	0.8

Click cells to compare fundamentals

About Kalvista Pharmaceuticals Financial Statements

Kalvista Pharmaceuticals investors use historical fundamental indicators, such as Kalvista Pharmaceuticals' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kalvista Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	25.2 M	26.5 M
Stock Based Compensation To Revenue	0.02	0.02

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kalvista Stock Based Compensation from 2010 to 2025

Latest Kalvista Pharmaceuticals' Stock Based Compensation Growth Pattern

Kalvista Stock Based Compensation Regression Statistics

Kalvista Stock Based Compensation History

Other Fundumenentals of Kalvista Pharmaceuticals

Kalvista Pharmaceuticals Stock Based Compensation component correlations

About Kalvista Pharmaceuticals Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Kalvista Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY